

ForPatients

by Roche

Ovarian Cancer

A clinical trial to look at how well cobimetinib works in combination with another drug called niraparib to slow, stop or reverse the course of ovarian cancer, and whether it works better when it is given with or without another drug called atezolizumab.

A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer

Trial Status
Completed

Trial Runs In
3 Countries

Trial Identifier
NCT03695380 2018-000631-27
YO40482

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The study will include a safety run-in phase (Stage 1) and a randomization phase (Stage 2). The purpose of Stage 1 is to evaluate the safety of cobimetinib when administered in combination with niraparib (Cohort 1) and cobimetinib with niraparib plus atezolizumab (Cohort 2). Stage 1 will enable patient enrollment in the randomized phase of the study (Stage 2) with both regimens at the recommended dose levels from Stage 1. Stage 2 is a randomized, dose-expansion phase, evaluating clinical outcomes in patients with advanced platinum-sensitive ovarian cancer. All patients will continue to receive study treatment until disease progression (according to "Response Evaluation Criteria in Solid Tumors" (RECIST), Version 1.1, unacceptable toxicity, death, or patient or investigator decision to withdraw, whichever occurs first.

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT03695380 2018-000631-27 YO40482
Trial Identifiers

Eligibility Criteria:

Gender
Female

Age
≥ 18 Years

Healthy Volunteers
No

ForPatients

by Roche

How does the YO40482 clinical trial work?

This clinical trial is recruiting people who have advanced ovarian cancer.

The purpose of this clinical trial is to test the safety and effectiveness of cobimetinib when given with another drug called niraparib, and whether it works better when given with or without another drug called atezolizumab.

How do I take part in this clinical trial?

To be able to take part in this clinical trial, you must have been diagnosed with advanced ovarian cancer and have already tried a specific chemotherapy, called platinum chemotherapy, once or twice.

If you think this clinical trial may be suitable for you and would like to take part, please talk to your doctor. If your doctor thinks that you might be able to take part in this clinical trial, he/she may refer you to the closest clinical trial doctor. They will give you all the information you need to make your decision about taking part in the clinical trial. You can also find the clinical trial locations on this page.

You will have some further tests to make sure you will be able to take the treatments given in this clinical trial. Some of these tests or procedures may be part of your regular medical care. They may be done even if you do not take part in the clinical trial. If you have had some of the tests recently, they may not need to be done again.

Before starting the clinical trial, you will be told about any risks and benefits of taking part in the trial. You will also be told what other treatments are available so that you may decide if you still want to take part.

While taking part in the clinical trial, if you are not currently pregnant but can become pregnant, you will need to either not have heterosexual intercourse or take contraceptive medication for safety reasons.

What treatment will I be given if I join this clinical trial?

This clinical trial has two Stages. The doses of cobimetinib and niraparib will be confirmed in Stage 1. If you have the BRCA mutation, you will only be able to enter Stage 1 of this trial. If you do not have the BRCA mutation you may be entered into either Stage 1 or Stage 2.

ForPatients

by Roche

Everyone who enters Stage 1 of this clinical trial will be split into 2 groups randomly (like flipping a coin) and given, as a starting dose, either:

- cobimetinib (3 tablets to swallow every day for 3 weeks and then not taken for 1 week) and niraparib (2 capsules to swallow every day)
- OR cobimetinib (3 tablets to swallow every day for 3 weeks and then not taken for 1 week) and niraparib (2 capsules to swallow every day) and atezolizumab (drug given into your vein every 2 weeks)

Depending on how patients responded to treatment in Stage 1 the doctors may change the dose of cobimetinib and/or niraparib before Stage 2. After the doses of niraparib and cobimetinib are confirmed in Stage 1, Stage 2 will open. Everyone who enters Stage 2 of this clinical trial will also be split into 2 groups randomly and given the same treatments as those listed for Stage 1.

Whether you join Stage 1 or Stage 2, you will have an equal chance of being placed in either treatment group. Doctors will be monitoring you for and side effects related to the treatment you have been given. In Stage 2, if you are in the group that is not being given atezolizumab and your cancer gets worse, you may be allowed to swap to the group that is being given atezolizumab.

How often will i be seen in follow-up appointments, and for how long?

You will be given the clinical trial treatment for as long as it can help you. You are free to stop this treatment at any time. After being given treatment, you will still be monitored by telephone call or clinic visits every 3 months. This will include checks to see how you are responding to the treatment and any side effects that you may be having.

What happens if i am unable to take part in this clinical trial?

If this clinical trial is not suitable for you, you will not be able to take part. Your doctor will suggest other clinical trials that you may be able to take part in or other treatments that you can be given. You will not lose access to any of your regular care.

For more information about this clinical trial see the **For Expert** tab on the specific ForPatient page or follow this link to ClinicalTrials.gov <https://clinicaltrials.gov/ct2/show/NCT03695380>

Trial-identifier: NCT03695380